Proactive Investors - Run By Investors For Investors

Scancell adds six ‘world-leading’ cancer specialists to advisory board ahead of Modi-1 trial

“The initial focus of the board will be to inform the clinical strategy for the planned Modi-1 clinical trial and to ensure the best possible outcome in several solid tumour indications”
cancer patient
Modi-1 is due to enter the clinic in the first quarter of 2020

Scancell Holdings PLC (LON:SCLP) has added six “world-leading” cancer specialists to its clinical advisory board as the drug developer prepares for its Modi-1 cancer treatment to enter the clinic early next year.

AIM-quoted Scancell’s clinical advisory boards now boasts some of the brightest and most respected cancer researchers that the UK has to offer.

READ: Scancell to begin UK arm of skin cancer trial within weeks

The University of Sheffield’s emeritus professor of medical oncology, Robert Coleman, is joined by Christian Ottensmeier, a professor of experimental cancer medicine treatment at the University of Southampton.

Imperial College London professor of oncology, Iain McNeish, Mount Vernon cancer centre’s lead breast cancer clinician David Miles, Nottingham University Hospital’s Stephen Chan and Poulam Patel, professor of clinical oncology at the University of Nottingham, have also joined the board.

“We are delighted to welcome all six experienced clinicians to our clinical advisory board and the creation of this Board is part of our wider strategy to fully develop and deliver the full potential of the Moditope platform across multiple tumour types,” said Scancell chief executive Cliff Holloway.

“The initial focus of the board will be to inform the clinical strategy for the planned Modi-1 clinical trial and to ensure the best possible outcome in several solid tumour indications, including ovarian cancer, head and neck cancer, and triple negative breast cancer.”

‘Significant progress’ made

Modi-1 is Scancell’s first drug using its Moditope technology. It acts to stimulate the production of killer CD4+ T cells that seek out and kill tumour cells which would otherwise be hidden from the immune system. 

A phase I/II study is set to begin in the first quarter of 2020, which will see Modi-1 trialled in patients with various types of cancer, including head and neck, breast and ovarian.

Scancell confirmed on Friday that preparation for the trial is well underway. A Scottish firm has now been chosen to manufacture and package the final Modi-1 product, while a preclinical toxicity testing programme got underway last month and is expected to be wrapped up later this year.

Holloway added: “Significant progress has been made towards completing the GMP manufacture of the Modi-1 product and the preclinical testing required prior to the anticipated start of the trial early in 2020.”

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

scientist in laboratory
May 24 2019
Here we take a closer look at healthcare investor NetScientific PLC (LON:NSCI)
test tubes
May 02 2019
Proactive takes a closer look at an innovative drugs company that has largely flown under the radar
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use